Methods and compositions for correction of organ dysfunction
AssigneeGenetic Disease Investigators, LLC
InventorDiana Driscoll
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
Claims59
A composition comprising:
- a choline compound;
- a cholinesterase inhibitor;
- and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
A composition consisting essentially of:
- 30 to 2,400 mg of at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;
- 75-300 mcg of huperzine A;
- 50 to 600 mg of Acetyl-L-Carnitine;
- and
- optionally including at least one of 10-180 mg Thiamin or Magnesium.
A composition consisting of:
- 30 to 2,400 mg of at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;
- 75 mcg-300 mcg of huperzine A;
- 50 to 600 mg of Acetyl-L-Carnitine;
- and
- optionally including at least one of 10-180 mg Thiamin or Magnesium.
A method of treating a autonomic dysfunctions or vascular diseases in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a choline compound;
- a cholinesterase inhibitor and Acetyl-L-Carnitine.
A method of treating a medical condition, comprising:
- identifying a subject having the disease;
- and
- providing the patient with a medical composition that comprises:
- a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;
- 75 mcg-300 mcg of huperzine A;
- 50 mg to 600 mg of Acetyl-L-Carnitine;
- and
- 10-180 mg Thiamin or Magnesium.
A vaginal composition comprising:
- at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;
- huperzine A;
- and Acetyl-L-Carnitine, wherein the composition is adapted for vaginal administration and is provided in an amount sufficient to treat one or more autonomic dysfunctions or vascular diseases.
A transdermal composition comprising:
- at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;
- huperzine A;
- and Acetyl-L-Carnitine, wherein the composition is adapted for transdermal administration and is provided in an amount sufficient to treat one or more autonomic dysfunctions or vascular diseases.
A rectal composition comprising:
- at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;
- huperzine A;
- and Acetyl-L-Carnitine, wherein the composition is adapted for rectal administration and is provided in an amount sufficient to treat one or more autonomic dysfunctions or vascular diseases.
A method for diagnosing post-ganglionic vagus nerve competency and effector organ function, comprising the steps of:
- identifying a patient suspected of having pre-ganglionic vagus nerve damage or symptoms thereof;
- providing the patient with an effective amount of transdermal, rectal or vaginal suppository, or subcutaneous nicotine;
- and
- determining the response of an effector organ, wherein if the effector organ functions following exposure to the nicotine, then the patient can be treated with a composition comprising a choline compound;
- a cholinesterase inhibitor;
- and Acetyl-L-Carnitine.
A method for treating pre-ganglionic vagus nerve damage or symptoms thereof comprising the steps of:
- identifying a patient suspected of having pre-ganglionic vagus nerve damage or symptoms thereof and
- providing the patient with an effective amount of transdermal, rectal or vaginal suppository, or subcutaneous nicotine sufficient to treat the pre-ganglionic vagus nerve damage or symptoms thereof.
Dependencies are inferred from the claim text.